236 related articles for article (PubMed ID: 6733002)
41. Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients.
Hong JM; Choi YC; Kim WJ
Yonsei Med J; 2009 Aug; 50(4):517-20. PubMed ID: 19718399
[TBL] [Abstract][Full Text] [Related]
42. Human brain phenytoin: correlation with unbound and total serum concentrations.
Friel PN; Ojemann GA; Rapport RL; Levy RH; Van Belle G
Epilepsy Res; 1989; 3(1):82-5. PubMed ID: 2917548
[TBL] [Abstract][Full Text] [Related]
43. Serum albumin-adjusted phenytoin levels: an approach for predicting drug efficacy in patients with epilepsy, suitable for developing countries.
Tandon M; Pandhi P; Garg SK; Prabhakar SK
Int J Clin Pharmacol Ther; 2004 Oct; 42(10):550-5. PubMed ID: 15516024
[TBL] [Abstract][Full Text] [Related]
44. Comparison of phenytoin determinations in plasma, plasma dialysate and saliva for control of antiepileptic therapy in children.
Brügmann G; Kleinau E; Nolte R; Petruch F
Klin Wochenschr; 1979 Jan; 57(2):93-4. PubMed ID: 762949
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic Drug Monitoring of Phenytoin by Simple, Rapid, Accurate, Highly Sensitive and Novel Method and Its Clinical Applications.
Shaikh AS; Guo R
Curr Pharm Biotechnol; 2017; 18(13):1098-1105. PubMed ID: 29437004
[TBL] [Abstract][Full Text] [Related]
46. Decreased plasma protein binding of phenytoin in patients on valproic acid.
Dahlqvist R; Borgå O; Rane A; Walsh Z; Sjöqvist F
Br J Clin Pharmacol; 1979 Dec; 8(6):547-52. PubMed ID: 391256
[TBL] [Abstract][Full Text] [Related]
47. Correlation between serum and salivary phenytoin concentrations in Thai epileptic children.
Liamsuwan S; Jaiweerawattana U
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S172-7. PubMed ID: 22043772
[TBL] [Abstract][Full Text] [Related]
48. The effect of combination therapy on the plasma concentrations of traditional antiepileptics: a retrospective study.
Sirmagul B; Atli O; Ilgin S
Hum Exp Toxicol; 2012 Oct; 31(10):971-80. PubMed ID: 22588177
[TBL] [Abstract][Full Text] [Related]
49. Spotlight on the continual applicability of routine plasma monitoring antiepileptic drugs in the treatment of epilepsy.
El Desoky E; Kandil MR; Afifi AH; Mostafa OA
Pharmacol Res; 1999 Apr; 39(4):269-74. PubMed ID: 10208756
[TBL] [Abstract][Full Text] [Related]
50. Steady-state anticonvulsant drug levels in epileptic patients.
Kokwaro GO; Kwasa TO; Indalo AA; Kibwage IO
East Afr Med J; 1996 Oct; 73(10):679-82. PubMed ID: 8997850
[TBL] [Abstract][Full Text] [Related]
51. Unbound plasma phenytoin concentrations measured using enzyme immunoassay technique on the cobas MIRA analyser--in vivo effect of valproic acid.
Sallustio BC; Morris RG
Ther Drug Monit; 1992 Feb; 14(1):9-13. PubMed ID: 1546396
[TBL] [Abstract][Full Text] [Related]
52. Serum protein binding kinetics of phenytoin in monotherapy patients.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Todaka K; Mitsuyama Y
J Clin Pharm Ther; 1998 Oct; 23(5):361-5. PubMed ID: 9875684
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic drug monitoring of antiepileptic drugs.
Shakya G; Malla S; Shakya KN; Shrestha R
JNMA J Nepal Med Assoc; 2008; 47(171):94-7. PubMed ID: 19079370
[TBL] [Abstract][Full Text] [Related]
54. Phenytoin and IgA concentrations in plasma and saliva in epileptic children.
Modéer T; Tomson G; Falk O; Rane A
Acta Paediatr Scand; 1981; 70(3):373-8. PubMed ID: 7246128
[TBL] [Abstract][Full Text] [Related]
55. Plasma and saliva concentrations of phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in relation to the incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients.
Ball DE; McLaughlin WS; Seymour RA; Kamali F
J Periodontol; 1996 Jun; 67(6):597-602. PubMed ID: 8794970
[TBL] [Abstract][Full Text] [Related]
56. Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants.
Ueshima S; Aiba T; Ishikawa N; Sato T; Kawasaki H; Kurosaki Y; Ohtsuka Y; Sendo T
J Clin Pharm Ther; 2009 Aug; 34(4):415-22. PubMed ID: 19583674
[TBL] [Abstract][Full Text] [Related]
57. Clinical evaluation of plasma free phenytoin measurement and factors influencing its protein binding.
Iwamoto T; Kagawa Y; Naito Y; Kuzuhara S; Okuda M
Biopharm Drug Dispos; 2006 Mar; 27(2):77-84. PubMed ID: 16308884
[TBL] [Abstract][Full Text] [Related]
58. Compliant populations: variability in serum concentrations.
Graves NM; Holmes GB; Leppik IE
Epilepsy Res Suppl; 1988; 1():91-9. PubMed ID: 3072193
[TBL] [Abstract][Full Text] [Related]
59. Audit of a monitoring service for free phenytoin.
Peterson GM; McLean S; von Witt RJ; Millingen KS
Br J Clin Pharmacol; 1985 May; 19(5):693-7. PubMed ID: 3890911
[TBL] [Abstract][Full Text] [Related]
60. Monitoring Protein-Unbound Valproic Acid Serum Concentrations in Clinical Practice.
Wallenburg E; Klok B; de Jong K; de Maat M; van Erp N; Stalpers-Konijnenburg S; Essink G; van Luin M
Ther Drug Monit; 2017 Jun; 39(3):269-272. PubMed ID: 28437285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
